ARVAC - A New Recombinant Coronavirus Disease 2019 (COVID-19) Vaccine

Clinical trial NCT05656508 · COMPLETED

Trial details

NCT number: NCT05656508
Sponsor: Laboratorio Pablo Cassara S.R.L.
Status: COMPLETED
Phase: Phase 1
Study type: INTERVENTIONAL

COVID-19 Vaccine

Start date: 2022-04-20
Primary completion: 2022-09-30
Enrollment: 80

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.